Rivoglitazone

This classification denotes an anti-diabetic agent with the molecular formula C20H19N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 3A3N0634Q6, chemically known as 2,4-thiazolidinedione, 5-((4-((6-methoxy-1-methyl-1h-benzimidazol-2-yl)methoxy)phenyl)methyl)-; but more generally known as rivoglitazone, which bears US NIH Compound Identifier 3055168. The term RIVOGLITAZONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 15 No. 3-4, 2001, List 46). Most nations, for tariff and trade purposes, schedule rivoglitazone under HS 29341000 and SITC 51579. As of Q4 2014, RIVOGLITAZONE remains US FDA's Preferred Term for this commodity. Rivoglitazone bears US NLM identifiers UMLS ID C1958863 and NCI Concept Code C72841. SMILES: CN1C2=C(C=CC(=C2)OC)N=C1COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4.